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Background: Changes in left ventricular (LV) activation after cardiac resynchronization 
therapy (CRT) influence survival but are difficult to quantify non-invasively.  
Methods and Results: We studied 527 CRT patients to assess whether non-invasive 
quantification of changes in LV activation, defined by change (Δ) in QRS area(QRSA), 
can predict outcomes after CRT. The study outcome was time until LV assist 
device(LVAD), cardiac transplant, or death. The 3-dimensional QRSA was measured 
from clinical 12 lead ECGs which were transformed into vectorcardiograms using the 
Kors method. QRSA was calculated as (QRSx2+QRSy2+QRSz2)1/2; ΔQRSA was 
calculated as post-QRSA minus pre-QRSA, where a negative value represents a reduction 
in LV activation delay. Kaplan Meier plots and multivariable Cox proportional hazards 
models were used to relate ΔQRSA area with outcomes after stratifying the population 
into quartiles of ΔQRSA. The median baseline QRSA of 93.6µVs decreased to 59.7µVs 
after CRT. Progressive reductions in QRSA with CRT were associated with a lower rate 
of LVAD, transplant, or death across patient quartiles(p<0.001). In Cox regression 
analyses, ΔQRSA was associated with outcomes independent of QRS morphology and 
other clinical variables [Q1(greatest decrease) vs. Q4(smallest change = reference), HR 
0.45, CI 0.30-0.70, p<0.001]. There was no interaction between ΔQRSA and QRS 
morphology.  
Conclusions: CRT induced ΔQRSA was associated with clinically meaningful changes 
in event free survival. ΔQRSA may be a novel target to guide lead implantation and 
device optimization.  
Key words: cardiac resynchronization therapy, vectorcardiography, dyssynchrony, 
electrocardiography, outcomes, heart failure  
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Introduction  
Cardiac resynchronization therapy (CRT) is a well-established therapy for patients with 
systolic heart failure and evidence of electrical dyssynchrony on the 12-lead ECG. 
Successful electrical resynchronization reduces overall left ventricular (LV) activation 
delays and is associated with improvements in LV structure and function,1,2 affording 
improvements in heart failure, quality of life, and survival. Although the importance of 
CRT induced improvements in LV activation are well recognized, these changes are 
difficult to quantify rapidly and non-invasively. Prior studies show that the change in 
QRS duration after CRT pacing is inconsistently associated with likelihood of CRT 
benefit.3,4 
Recently published work from our group5 and others6-8 suggests that 12-lead ECG 
derived vectorcardiographic (VCG) representations of ventricular activation may be 
useful for identifying an electrical substrate amendable to CRT. In these studies, a larger 
VCG derived QRS area (QRSA) on the baseline ECG was associated with increased 
likelihood of CRT response7 and more favorable long-term outcomes5,8 independent of 
QRS duration and morphology. These findings strongly suggest that QRSA is a robust 
non-invasive measure of LV activation delay. Based on these findings we sought to 
determine if non-invasive quantification of changes in LV activation, defined by absolute 
change in QRSA (ΔQRSA), could predict outcomes after CRT. We hypothesized that 
CRT induced reductions in QRSA would be associated with improved long-term 
outcomes.  
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Methods 
Study population 
We performed a retrospective analysis of patients who received a de novo CRT with 
defibrillator from April 2006 – September 2015 at Duke University Hospital. LV lead 
targeting was generally performed using an anatomic approach, guided rby occlusive 
coronary sinus venography, with the goal to implant in a lateral branch and maximize 
distance from the RV lead. For patients with quadripolar leads, we selected the electrode 
pair with maximal electrical delay that had an acceptable capture threshold without 
phrenic nerve stimulation. Echocardiographic optimization was performed rarely, usually 
in the setting of CRT non-response. Patients were first identified using an institutional 
dataset prepared for submission to the National Cardiovascular Data Registry. For this 
study, patients were required to have an LV ejection fraction (LVEF) of ≤35%, a QRS 
≥120ms, and a digital ECG at baseline (≤180 days prior to CRT implantation) and ≤ 90 
days after the index procedure. Patients were excluded if they died prior to discharge or if 
a follow-up ECG did not demonstrate evidence of CRT pacing. If multiple ECGs were 
available in the allowable pre- and/or post-CRT time frame we utilized the ECG closest 
to the procedure date. The study was approved by the Duke Institutional Review Board. 
ECG and VCG Analyses  
Clinically obtained ECGs were reanalyzed in the GE MUSE Cardiology Information 
System version 8.0.2.10132 with analysis software version 241 (GE Healthcare, Chicago, 
IL, USA) and exported in XML format. QRS morphology was designated by two readers 
(DF and KE) blinded to outcome. Left bundle branch block (LBBB) morphology was 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
further divided into strict and non-strict LBBB using the Strauss criteria.9 Notably, the 
Strauss criteria incorporate information on both QRS duration and characteristics (e.g. 
notching). QRS onset and offset and thereby QRS duration as detected by the software 
were over read and manually corrected if needed. 
VCGs were derived from the XML files using customized MATLAB software 
(MathWorks, Inc., Natick, MA, USA) using the Kors matrices10 based on previous data5 
suggesting VCGs resulting from the Kors transformation were more predictive of 
outcomes after CRT compared to Inverse Dower transformed VCGs.11 We calculated the 
QRSA5,7 for each pre- and post- CRT ECG using the median complex. The area under the 
depolarization curve was calculated for each of the 3 planes (X,Y,Z). The 3-dimensional 
QRSA was calculated as (QRSx2 + QRSy2 +QRSz2)1/2. The absolute CRT induced 
change in QRS area (ΔQRSA) was calculated as post-CRT QRSA minus pre-CRT 
QRSA; with this convention, a negative value represents a reduction in LV activation 
time which we hypothesized would represent a favorable prognostic sign. In contrast, a 
ΔQRSA > 0 (i.e. a positive value) would represent an overall increase in LV activation 
time which we hypothesized would identify increased risk for adverse outcomes.  
End Points 
The study endpoint was incident left ventricular assist device (LVAD), cardiac transplant, 
or death. End point occurrence was determined via a May 24, 2017 query of the Duke 
Enterprise Data Unified Content Explorer, which incorporates data from billing claims, 
hospital records, and the Social Security Death Index.12  
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Statistical Analyses 
Baseline characteristics of the overall study population and after stratification by quartile of 
ΔQRSA were described using proportions for categorical variables and medians and interquartile 
ranges for continuous variables. The 1st ΔQRSA quartile was defined as the quartile with the most 
negative ΔQRSA (greatest decrease in QRSA with CRT), the 4th ΔQRSA quartile was defined as 
the quartile with the most positive ΔQRSA (smallest decrease or increase in QRSA with CRT), 
and the 2nd and 3rd quartiles represented intermediate groups. Differences between groups were 
tested using the Chi-square test for categorical variables and Kruskal Wallis Rank Sum test for 
continuous variables. Glomerular filtration rate was estimated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation.13 
The unadjusted long term association between ΔQRSA quartile and time until transplant, 
LVAD, or death, was visually depicted using a Kaplan Meier plot and differences were 
assessed using the Log Rank test. The adjusted association between ΔQRSA quartile and 
time until transplant, LVAD, or death, was assessed using Cox proportional hazards 
models with Q4 as the reference group. Schoenfeld Residual plots were created to 
confirm no violation of the proportional hazards assumption. Adjustment variables 
included age, sex, atrial fibrillation or flutter, ischemic heart disease, ejection fraction, 
QRS morphology, beta blocker use, ACEi or ARB use, diabetes, NYHA class, and 
reduced eGFR, defined as <60 mL/min/1.73m2. We assessed for interactions between 
model variables prior to inclusion in Cox regression analyses. The association between 
ΔQRSA (across the continuous range) and outcomes was assessed using an adjusted 
restricted cubic spline with 3 knots with a ΔQRSA of 0 being assigned a hazard ratio of 
1. Several subgroup analyses were performed handling ΔQRSA as a continuous variable 
in unadjusted cox regression analyses. Statistical analysis was performed in RStudio 
This article is protected by copyright. All rights reserved. 
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version 1.1447 (RStudio, Inc, Boston, MA, USA) running R version 3.4.4 (R Foundation 
for Statistical Computing, Vienna, Austria). A p<0.05 was considered statistically 
significant for all analyses except for during interaction testing where a prior decision 
was made to use p<0.01 to account for multiple testing.  
Results 
A total of 1001 patients underwent CRT-D implant during the study period. After 
excluding patients with missing ECG (n= 407), QRS duration <120ms (n=39), 
LVEF>35% (n=18), death prior to discharge (n=7), non-CRT paced QRS morphology on 
the follow-up ECG (n=1),or poor quality follow-up ECG (n=2), a total of 527 patients 
were available for analysis. The overall study population was older (67.7 years, IQR 
57.6-75.2), predominantly male (69.4%), and demonstrated a severely reduced ejection 
fraction (25.0%, IQR 20.0-30.0) with advanced HF symptoms (81.2% NYHA III 
symptom class). Medical comorbidities were common, including ischemic 
cardiomyopathy (54.1%), hypertension (71.5%), diabetes (38.3%), and atrial fibrillation 
or flutter (34.2%). LBBB was present in 64.2% of patients and the median QRS duration 
was 160 ms (IQR 144-180). Baseline clinical and electrocardiographic characteristics are 
depicted in Tables 1 and 2, respectively.  
The median baseline QRSA of the overall population was 93.6µVs (IQR 61.3-127.3) and 
this decreased to 59.7µVs (IQR 41.7-82.8) with CRT pacing (p<0.0001)(Figure 1). After 
the overall population was stratified by quartile of ΔQRSA, the heterogeneity in ΔQRSA 
across the population became evident (Figure 1). Patients with the most negative 
ΔQRSA (largest reduction in LV activation delay) were more commonly female, had 
This article is protected by copyright. All rights reserved. 
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non-ischemic cardiomyopathy, a longer baseline QRS duration, LBBB or RV paced 
ECG, and demonstrated a larger baseline QRSA. Patients with a smaller reduction (or 
even increase) in QRSA with CRT more commonly had RBBB, atrial fibrillation or 
flutter, chronic lung disease, a prior ICD, or treatment with amiodarone. Baseline clinical 
and electrocardiographic characteristics by ΔQRSA quartile are depicted in Tables 1 and 
2, respectively.  
CRT delivery strategies are depicted in Table 3. Median paced AV delay was 130ms 
(IQR 130-170ms) and median sensed AV delay was 100ms (IQR 100-120ms); AV delays 
did not vary by ΔQRSA quartile (p=0.62 and p=0.78, respectively). VV offset 
programing was variable and devices were most commonly programmed to deliver 
simultaneous biventricular stimulation. AdaptiveCRT was programmed on in 10.8% of 
patients and was somewhat more common among patients in Q1 (overall p=0.07). 
Quadriploar leads were implanted in 15% of patients and the proportion did not vary by 
ΔQRSA quartile (p=0.15). of note, quadripolar leads and AdaptiveCRT programming 
were not clinically available until later in the study period.  
The median follow-up time was 1137 (interquartile range: 621-2004) days. Of the 247 
patients who met the primary endpoint, 17 underwent LVAD implantation, 24 underwent 
heart transplantation, and 206 died. ΔQRSA (by quartile) was strongly associated with 
incident LVAD, transplant, or death in an unadjusted Log Rank analysis (p<0.001, 
Figure 2). Examination of the Kaplan Meier curve demonstrates that greater reductions 
in QRSA were associated with increasingly favorable long term outcomes across study 
quartiles. An adjusted Cox proportional hazards model (with Q4 as the reference group) 
demonstrated that ΔQRSA was significantly associated with outcomes (Figure 3); 
This article is protected by copyright. All rights reserved. 
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although the point estimate suggested that Q1, Q2, and Q3, all had more favorable 
outcomes compared to Q4, the only difference reaching statistical significance was the 
Q1 vs. Q4 comparison. Results were similar with adjustment for amiodarone use, which 
was most common in Q4. There were no statistical interactions between baseline QRS 
morphology, ΔQRSA, and outcome. An adjusted spline analysis (Figure 4) demonstrated 
that the relationship between ΔQRSA and incident LVAD, transplant, or death was 
preserved across the continuous range.  
LBBB  
The LBBB cohort (n=338) was subsequently divided into ΔQRSA quartiles (similar to 
the approach for overall population) for subgroup analyses. Compared to Q4 patients 
(those with the smallest decrease or an increase in QRSA with CRT), Q1 (adjusted HR 
0.39, CI 0.23-0.65) and Q2 (adjusted HR 0.55, CI 0.34-0.89) patients were significantly 
less likely to experience transplant, LVAD, or death (Figure 5).  
Subgroup analyses 
Additional subgroup analyses were performed handling ΔQRSA as a continuous variable 
(Table 4). In these analyses, ΔQRSA demonstrated predictive value regardless of age, 
sex, PR interval, QRS duration or history of coronary artery disease. ΔQRSA 
demonstrated predictive value among LBBB (but not non-LBBB or RV paced) patients, 
those with a higher ejection fraction (≥20%), and those with a greater baseline QRSA. 
ΔQRSA significantly predicted outcomes among patients with no atrial arrhythmias; the 
association among patients with atrial arrhythmias demonstrated borderline significance 
(p=0.052).  
This article is protected by copyright. All rights reserved. 
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Discussion 
This study, which related non-invasively assessed CRT induced changes in LV activation 
to clinical outcomes, has several relevant findings. First, although the overall study 
population demonstrated reductions in QRSA (consistent with CRT induced 
improvements in LV activation), significant variability existed across the population, and 
a significant minority of the overall population demonstrated worsened LV activation 
with CRT. Second, greater reductions in QRSA were associated with female sex, LBBB, 
longer baseline QRS duration, larger baseline QRS area, non-ischemic cardiomyopathy, 
and absence of atrial arrhythmias or lung disease. Third, CRT-induced reductions in 
QRSA were associated with clinically meaningful differences in event free survival. 
Finally, the relationship between ΔQRSA and outcomes was preserved across the 
continuous range and no clinically relevant threshold could be identified. These study 
findings have important implications for our overall understanding of the impact of CRT 
on LV activation and suggest that ΔQRSA is a novel and powerful predictor of CRT 
outcomes that could have the potential to improve LV lead implantation and device 
optimization algorithms.  
Our understanding of the importance of the electrical substrate on outcomes after CRT 
has improved over the past two decades.14 Early landmark CRT trials enrolled patients 
with QRS prolongation regardless of QRS morphology based on the general assumption 
that patients with QRS prolongation had at least some amount of left ventricular 
activation delay.15-18 Subsequent analyses demonstrating patients with LBBB were more 
likely to benefit from CRT3,19 (presumed due to greater extent of LV activation delay)20 
have underscored the importance of the electrical substrate. However, a significant 
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minority of LBBB patients do not respond to CRT19,21 and an important minority of non-
LBBB patients do appear to benefit from CRT22,23 although this remains controversial. 
Furthermore, it is increasingly recognized that optimal LV lead position24-26 and device 
programming algorithms27 affect CRT outcomes as they directly impact the activation 
wavefronts responsible for LV depolarization. Although prior work1,2 has compared 
baseline and paced ECG activation patterns to predict CRT response in LBBB patients, it 
has relied on complex, labor intensive scoring systems which may be challenging to 
integrate into a busy clinical practice.  
ΔQRSA represents a powerful summative parameter than incorporates information on the 
complex interaction between the baseline electrical substrate and the CRT induced 
activation wavefronts. Although patients with the greatest reduction in QRSA (i.e. most 
negative ΔQRSA) commonly had a LBBB, the association between ΔQRSA and 
outcomes was statistically independent of QRS morphology (as well as sex, 
cardiomyopathy etiology, and other characteristics commonly associated with CRT 
response). Furthermore, the magnitude of the association between ΔQRSA and outcomes 
was greater among the LBBB patients (compared to the overall cohort). These findings 
confirm that ΔQRSA is much more than a proxy for QRS morphology, but rather a 
powerful measure of the effectiveness of resynchronization and novel predictor of CRT 
response.  
Several studies have demonstrated that clinical outcomes are improved when the LV lead 
is implanted in a location with delayed electrical activation, compared to either QRS 
onset24,25,28-30 or the sensed signal on the RV lead.31 Importantly, emerging evidence has 
suggested that (1) an optimal electrical location does not always correspond to the 
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anatomic segments that are most commonly associated with CRT response and (2) 
assessment of electrical delay may improve outcomes among patients at high risk for 
CRT non-response.30  
Despite the mounting data and compelling physiologic rational for incorporating 
electrical delay into a care strategy, there are several limitations to this strategy. Due to 
the anisotropic nature of wavefront propagation in ventricular myocardium (which often 
has regions of functional block), it cannot be assumed that the site of latest activation 
(delayed conduction to a site) necessarily represents the best site for LV pacing (where a 
wavefront is propagating away from a site). Thus, electrical delay is an indirect measure 
of the potential for resynchronization with pacing from a given site. Furthermore, use of 
electrical location alone to guide lead implantation and programming would leave the 
electrophysiologist unable to understand the potential benefit of using LV only pacing 
relative to biventricular pacing, V-V offset, and multipoint pacing. Importantly, ΔQRSA 
is a quantitative, continuous measure that directly measures the quality of 
resynchronization. Further studies are required to compare ΔQRSA relative to LV 
electrical delay and determine if a ΔQRSA guided approach can result in improved 
patient outcomes.  
Potential Clinical Implications and Future Directions 
ΔQRSA is a robust representation of the complex interaction between electrical substrate 
and CRT. If QRSA calculation were added to commercially available ECG analysis 
software, it would allow for many potentially useful applications, including assessment of 
CRT candidacy prior to device implantation, optimization of LV lead targeting, and risk 
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prediction and ECG based device optimization after CRT implantation. Future research is 
required to determine if ΔQRSA guided LV lead implantation and CRT optimization can 
improve reverse remodeling and long term outcomes among CRT patients. Importantly, 
continuous device based ΔQRSA measurements would allow for ongoing iterative 
optimization of single and multisite LV pacing during CRT therapy.  
Limitations 
This study has several important limitations including the retrospective study design and 
single center nature. There are several differences in baseline characteristics across 
∆QRSA quartiles; as with any retrospective analysis, statistical adjustment may be 
incomplete and the possibility of residual confounding remains. ΔQRSA was calculated 
based on a single follow-up ECG which does not capture subsequent changes in LV 
activation due to device optimization; however, device optimization is rarely performed 
at our institution. Non-fatal endpoints (LVAD and transplant) were obtained from billing 
records and were not adjudicated based on blinded committee assessment and mode of 
death was not available. We were unable to assess the association between ΔQRSA and 
changes in NYHA class or quality of life as these scores were not routinely documented 
during routine clinical care. LV lead implantation in this study may not be optimized for 
non-LBBB patients; therefore it is possible that non-LBBB patients might demonstrate a 
greater decrease in QRSA with a different clinical implant strategy. QLV was 
infrequently measured during the study period and therefore we are unable to compare 
LV lead electrical delay and ΔQRSA. The study was conducted at a quaternary care 
center and therefore the results may not be generalizable to other patient care settings.  
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Conclusions  
ΔQRSA is a robust representation of the complex interaction between a patient’s 
electrical substrate and CRT pacing. Greater reductions in QRSA were associated with 
female sex, LBBB, longer QRS duration, non-ischemic cardiomyopathy and other 
characteristics associated with CRT response. CRT induced reductions in QRSA were 
associated with clinically meaningful differences in event free survival. ΔQRSA may be a 
novel target to guide lead implantation and device optimization.  
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Figures 
Figure 1. Bar graphs demonstrating pre-CRT QRS area (blue) and post-CRT QRS area 
(orange) overall and by ΔQRSA quartiles. The number over each pair of bars represents the 
average change in QRSA as calculated by subtracting the post-CRT QRSA from the pre-CRT 
QRSA and therefore a reduction in QRSA is indicated by a negative value.  
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Figure 2. Kaplan Meier curve depicting the relationship between ΔQRSA quartile and 
incidence of LVAD, transplant, or death. Q1 had the greatest average reduction in QRSA and 
Q4 had an average increase in QRSA.  
 
 
Figure 3. Forest plot depicting the adjusted association between ΔQRSA quartile and time 
until LVAD, transplant or death using an adjusted Cox proportional hazard model with Q4 as 
the reference. Adjusted for age, sex, atrial fibrillation or flutter, ischemic heart disease, ejection 
fraction, QRS morphology, beta blocker use, ACEi or ARB use, diabetes, NYHA class, and 
reduced eGFR, defined as <60 mL/min/1.73m2.  
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Figure 4. Adjusted spline function depicting the relationship between ΔQRSA across the 
continuous range and risk for LVAD, transplant, or death. Adjusted for age, sex, atrial 
fibrillation or flutter, ischemic heart disease, ejection fraction, QRS morphology, beta blocker 
use, ACEi or ARB use, diabetes, NYHA class, and reduced eGFR, defined as <60 
mL/min/1.73m2.  
 
Figure 5. Forest plot depicting the adjusted association between ΔQRSA quartile and time 
until LVAD, transplant or death using an adjusted Cox proportional hazard model in the LBBB 
only cohort (n=338) with Q4 as the reference. Adjusted for age, sex, atrial fibrillation or flutter, 
ischemic heart disease, ejection fraction, QRS morphology, beta blocker use, ACEi or ARB use, 
diabetes, NYHA class, and reduced eGFR, defined as <60 mL/min/1.73m2.  
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Tables 
 
Table 1. Baseline clinical characteristics of the overall population after stratification by ΔQRSA  
Variable Total (n=527) Q1 (n=132) Q2 (n=132) Q3 (n=131) Q4 (n=132) p-
value 
Age median [iqr] 67.7 [57.6, 75.2] 68.5 [55.8, 76.7] 67.4 [57.5, 73.3] 66.7 [59.4, 75.2] 68.0 [58.8, 75.2] 0.93 
Female 161 (30.6) 52 (39.4) 48 (36.4) 24 (18.3) 37 (28.0) <0.001 
Race       
Black 104 (19.7) 31 (23.5) 28 (21.2) 26 (19.8) 19 (14.4)  
White 292 (55.4) 71 (53.8) 76 (57.6) 75 (57.3) 70 (53.0)  
Missing 113 (21.4) 25 (18.9) 22 (16.7) 25 (19.1) 41 (31.1)  
Other 18 (3.4) 5 (3.8) 6 (4.5) 5 (3.8) 2 (1.5) 0.15 
Hispanic Ethnicity 8 (1.5) 
 
3 (2.3) 2 (1.5) 0 (0.0) 3 (2.3) 0.39 
Ejection Fraction  25.0 [20.0, 30.0] 
 
25.0 [19.2, 30.0] 25.0 [20.0, 30.0] 25.0 [20.0, 30.0] 20.0 [15.0,30.0] 0.22 
Ischemic 
Cardiomyopathy 
285 (54.1) 
 
56 (42.4) 69 (52.3) 77 (58.8) 83 (62.9) 0.005 
Prior PCI 126 (24.0) 
 
23 (17.4) 33 (25.0) 38 (29.0) 32 (24.6) 0.17 
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 CABG 167 (31.7)  30 (22.7) 39 (29.5) 47 (35.9) 51 (38.9) 0.024 
NYHA Class       
I 16 (3.0) 4 (3.0) 5 (3.8) 6 (4.6) 1 (0.8)  
II 64 (12.1) 19 (14.4) 18 (13.6) 15 (11.5) 12 (9.1)  
III 428 (81.2) 104 (78.8) 105 (79.5) 108 (82.4) 111 (84.1)  
IV 19 (3.6) 5 (3.8) 4 (3.0) 2 (1.5) 8 (6.1) 0.38 
eGFR 60.0 [42.5, 76.0] 
 
65.5 [49.8, 81.0] 56.5 [37.0,77.0] 60.0 [39.5, 79.0] 55.5 [42.0,69.2] 0.008 
Dialysis 14 (2.7) 
 
2 (1.5) 4 (3.0) 4 (3.1) 4 (3.0) 0.83 
Primary prevention 
ICD 
461 (87.5) 
 
120 (90.9) 114 (86.4) 115 (87.8) 112 (84.8) 0.49 
Prior ICD 108 (20.5) 
 
16 (12.1) 28 (21.2) 36 (27.5) 28 (21.2) 0.021 
Diabetes 202 (38.3) 
 
45 (34.1) 51 (38.6) 49 (37.4) 57 (43.2) 0.50 
Hypertension 377 (71.5) 
 
90 (68.2) 90 (68.2) 98 (74.8) 99 (75.0) 0.40 
Atrial Fibrillation or 
Flutter 
180 (34.2) 
 
33 (25.0) 41 (31.1) 50 (38.2) 56 (42.4) 0.015 
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Chronic Lung 
Disease 
117 (22.2) 
 
17 (12.9) 31 (23.5) 35 (26.7) 34 (25.8) 0.026 
Cerebrovascular 
Disease 
72 (13.7) 
 
14 (10.6) 16 (12.1) 22 (16.8) 20 (15.3) 0.44 
Amiodarone 92 (17.5) 
 
11 (8.3) 27 (20.5) 23 (17.6) 31 (23.5) 0.008 
Beta Blocker 468 (88.8) 
 
122 (92.4) 118 (89.4) 112 (85.5) 116 (87.9) 0.34 
ACE/ARB 410 (77.8) 
 
113 (85.6) 99 (75.0) 101 (77.1) 97 (73.5) 0.08 
Digoxin 87 (16.5) 
 
16 (12.1) 18 (13.6) 25 (19.1) 28 (21.2) 0.15 
Diuretic 449 (85.2) 
 
111 (84.1) 109 (82.6) 112 (85.5) 117 (88.6) 0.55 
Table 2. Baseline electrocardiographic characteristics of the overall population and after stratification by ΔQRSA 
 Total (n=527) Q1 (n=132) Q2 (n=132) Q3 (n=131) Q4 (n=132) P-
value 
QRS Morphology       
Strict LBBB 266 (50.5) 
 
93 (70.5) 70 (53.0) 63 (48.1) 40 (30.3)  
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 Non-strict LBBB 72 (13.7)  2 (1.5) 15 (11.4) 30 (22.9) 25 (18.9)  
other 4 (0.8) 
 
0 (0.0) 1 (0.8) 2 (1.5) 1 (0.8)  
RBBB 20 (3.8) 0 (0.0) 4 (3.0) 5 (3.8) 11 (8.3)  
RBBB + LAFB 41 (7.8) 1 (0.8) 7 (5.3) 6 (4.6) 27 (20.5)  
RBBB + LPFB 3 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 3 (2.3)  
RV paced 91 (17.3) 35 (26.5) 32 (24.2) 16 (12.2) 8 (6.1)  
IVCD 30 (5.7) 
 
1 (0.8) 3 (2.3) 9 (6.9) 17 (12.9) <0.001 
Baseline Rhythm       
Normal sinus 
rhythm 
285 (54.1) 
 
95 (72.0) 73 (55.3) 66 (50.4) 51 (38.6)  
Atrial paced 41 (7.8) 
 
13 (9.8) 10 (7.6) 10 (7.6) 8 (6.1)  
Atrial fibrillation 75 (14.2) 10 (7.6) 16 (12.1) 21 (16.0) 28 (21.2)  
Atrial flutter 11 (2.1) 4 (3.0) 3 (2.3) 3 (2.3) 1 (0.8)  
1st degree AV 
block 
89 (16.9) 
 
7 (5.3) 23 (17.4) 23 (17.6) 36 (27.3)  
2nd degree AV 
block, Type I 
2 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.5)  
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Table 3. CRT delivery in the overall population and after stratification by ΔQRSA  
Variable Total (n=527) Q1 (n=132) Q2 (n=132) Q3 (n=131) Q4 (n=132) p-value 
PAVD 130.0 [130.0, 
170.0] 
140.0 [130.0, 
170.0] 
135.0 [130.0, 
170.0] 
130.0 [130.0, 
150.0] 
130.0 [130.0, 
170.0] 
0.62095 
2nd degree AV 
block, Type II 
3 (0.6) 0 (0.0) 0 (0.0) 2 (1.5) 1 (0.8)  
3rd degree AV 
block 
12 (2.3) 
 
1 (0.8) 4 (3.0) 3 (2.3) 4 (3.0)  
Other 8 (1.5) 2 (1.5) 3 (2.3) 2 (1.5) 1 (0.8) <0.001 
Atrial Rate 75.0 [66.0, 
85.0] 
75.0 [68.2, 85.0] 75.0 [66.0, 
84.5] 
73.0 [61.0, 
86.0] 
75.0 [65.0, 
85.0] 
0.75 
missing 8 2 1 2 3  
PR Interval 182.0 [162.0, 
206.0] 
172.0 [154.0, 
190.0] 
184.0 [162.0, 
206.0] 
186.0 [168.0, 
206.0] 
194.0 [173.0, 
220.0] 
<0.001 
missing 122 19 30 32 41  
QRS Duration 160.0 [144.0, 
180.0] 
174.0 [157.5, 
188.5] 
166.0 [152.0, 
181.5] 
152.0 [141.0, 
174.0] 
142.0 [132.0, 
160.5] 
<0.001 
QT Interval 458.0 [426.0, 
488.0] 
465.0 [440.0, 
490.5] 
463.0 [425.5, 
490.0] 
452.0 [418.0, 
492.0] 
451.0 [418.5, 
476.5] 
0.29 
QT Corrected 505.0 [475.0, 
532.0] 
517.0 [495.0, 
547.2] 
507.5 [480.8, 
535.2] 
492.0 [465.0, 
523.0] 
492.5 [470.0, 
527.2] 
<0.001 
QRS Area 93.6 [61.3, 
127.3] 
141.8 [121.2, 
168.7] 
98.4 [77.5, 
120.1] 
75.2 [53.8, 
99.6] 
51.2 [32.7, 
81.7] 
<0.001 
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 NA 100 20 26 22 32  SAVD 100.0 [100.0, 120.0] 100.0 [100.0, 120.0] 100.0 [100.0, 120.0] 100.0 [100.0, 120.0] 100.0 [100.0, 120.0] 0.77615 
NA 123 26 32 30 35  
VV Pre-excitation       
RV, ≥40 ms 5 (0.9) 1 (0.8) 1 (0.8) 1 (0.8) 2 (1.5)  
RV, 30 ms 3 (0.6) 1 (0.8) 0 (0.0) 1 (0.8) 1 (0.8)  
RV, 20 ms 9 (1.7) 2 (1.5) 1 (0.8) 2 (1.5) 4 (3.0)  
RV, 10 ms 7 (1.3) 0 (0.0) 6 (4.5) 1 (0.8) 0 (0.0)  
LV, 0 ms 221 (41.9) 59 (44.7) 53 (40.2) 55 (42.0) 54 (40.9)  
LV, 10 ms 14 (2.7) 1 (0.8) 2 (1.5) 6 (4.6) 5 (3.8)  
LV, 20 ms 37 (7.0) 10 (7.6) 12 (9.1) 7 (5.3) 8 (6.1)  
LV, 30 ms 20 (3.8) 10 (7.6) 5 (3.8) 3 (2.3) 2 (1.5)  
LV, ≥40 ms 44 (8.3) 13 (9.8) 10 (7.6) 13 (9.9) 8 (6.1)  
NA 167 (31.7) 35 (26.5) 42 (31.8) 42 (32.1) 48 (36.4) 0.11741 
 
Adaptive CRT 57 (10.8) 
 
22 (16.7) 13 (9.8) 13 (9.9) 9 (6.8) 0.06855 
 
Quadripolar leads 79 (15.0) 
 
28 (21.2) 17 (12.9) 17 (13.0) 17 (12.9) 0.14788 
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 LV = left ventricle, NA = not available, PAVD = paced atrioventricular delay, RV = right ventricle, SAVD = sensed atrioventricular delay, VV = ventriculoventricular   
Table 4. Association between ΔQRSA and outcomes among key 
patient subgroups 
 Hazard Ratio (for 
each 1µVs decrease 
in QRSA)  
P-value  
Age (median 67.73 yrs)   
≤median (n=263) 0.993 0.001 
>median (n=264) 0.992 <0.0001 
Sex   
Male (n=366) 0.995 0.003 
Female (n=161) 0.987 <0.0001 
Ejection Fraction   
<20 (n=123) 0.998 0.359 
≥20 (n=404) 0.990 <0.0001 
QRS morphology   
LBBB (n=338) 0.990 <0.0001 
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 RV paced (n=91) 0.994 0.112 Non-LBBB (n=98)  0.999 0.835 
PR interval   
≥200 (n=129) 0.995 0.075 
<200 (n=276) 0.994 0.002 
QRSd   
≥150 (n=349) 0.994 0.0008 
<150 (n=178) 0.991 0.0007 
Baseline QRS Area 
(median 93.57 µVs) 
  
<median (n=263) 0.998 0.491 
≥median (n=264) 0.995 0.029 
Atrial fibrillation or 
flutter 
  
Yes (n=180) 0.996 0.052 
No (n=347) 0.992 <0.0001 
Coronary Artery 
Disease 
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 Yes (n=285) 0.995 0.008 No (n=242) 0.991 0.0001 
CRT implantation Year   
2006-2010 
(n=273) 
0.993 <0.0001 
2011-2015 
(n=254) 
0.992 0.002 
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